China Medical System Holdings (HKSE:00867) 3-Year EPS without NRI Growth Rate : -0.60% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is China Medical System Holdings 3-Year EPS without NRI Growth Rate?

China Medical System Holdings's EPS without NRI for the six months ended in Dec. 2023 was HK$0.21.

During the past 12 months, China Medical System Holdings's average EPS without NRI Growth Rate was -13.50% per year. During the past 3 years, the average EPS without NRI Growth Rate was -0.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 10.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of China Medical System Holdings was 44.80% per year. The lowest was -46.90% per year. And the median was 16.90% per year.

Competitive Comparison of China Medical System Holdings's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Medical System Holdings's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where China Medical System Holdings's 3-Year EPS without NRI Growth Rate falls into.

China Medical System Holdings 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

China Medical System Holdings (HKSE:00867) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

China Medical System Holdings 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of China Medical System Holdings's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

China Medical System Holdings (HKSE:00867) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Medical System Holdings Ltd (HKSE:00867) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

2M7C:Germany

Address

510 King’s Road, Unit 2106, 21st Floor, North Point, Island Place Tower, Hong Kong, HKG

Website

http://www.cms.net.cn

China Medical System Holdings Ltd is active in the healthcare segment. It is one of the leading China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil; Salofalk; Combizym; Ganfule Capsules; Xidakang; Hirudoid; and others. Geographically, it derives revenue from China.

Executives

Treasure Sea Limited	2101 Beneficial owner
Lam Kong	2201 Interest of corporation controlled by you

China Medical System Holdings (HKSE:00867) Headlines

No Headlines